Investment Opportunity
Transforming NHS primary care with AI-powered clinical decision support
Investment Highlights
Proven Clinical Need
NHS waiting times at record highs. Primary care under immense strain. GPs seeing 30+ patients daily with limited diagnostic support.
Clear Market Opportunity
8,000+ GP practices in UK. 60M+ consultations annually. Minimal AI-powered diagnostic support currently deployed at scale.
Regulatory Clarity
Well-defined MHRA pathway as Class IIb SaMD. ISO standards established. Clinical validation framework proven by competitors.
Early-Stage Entry
Pre-seed valuation. MVP complete. Clear 12-18 month path to revenue. First-mover advantage in NHS primary care AI diagnostics.
The Problem
NHS Primary Care Crisis
- Record Waiting Times: Patients waiting weeks for GP appointments
- Clinician Burnout: GPs seeing 30-40 patients daily with limited time for each
- Diagnostic Delays: Simple conditions taking months to diagnose due to capacity constraints
- Cost Pressure: NHS budgets stretched while demand increases
- Limited Tools: Most GPs lack AI-powered diagnostic decision support
The Impact: Patients face unnecessary anxiety and treatment delays. GPs struggle with workload. The NHS wastes resources on preventable escalations. HeAIth addresses this at the critical first moment of patient assessment.
Our Solution
HeAIth is an AI-powered clinical decision support tool designed specifically for NHS primary care, providing evidence-based diagnostic recommendations at the point of care.
Key Differentiators
Built FOR Doctors WITH Doctors
Clinical Advisory Board of practicing GPs guides every product decision. Not a tech solution imposed on clinicians.
NHS-First Design
Designed for NHS workflows, UK regulatory standards, and British clinical practice from day one.
Early Diagnostic Focus
Targets the first moment of patient assessment where AI can have maximum impact on efficiency and outcomes.
Cost Commitment: Below £1 Per Diagnosis
We pledge to keep cost per diagnosis below £1 in real terms from 2025. While future algorithms may cost more than £0.30 to deliver improved accuracy and usability, our commitment is maintaining affordability below £1 to ensure NHS accessibility and clear ROI.
Our Cost Commitment
Below £1 Per Diagnosis Pledge
We commit to keeping the cost per diagnosis below £1 in real terms from 2025, ensuring HeAIth remains accessible and provides clear ROI for NHS trusts and GP practices.
Our Approach to Sustainable Pricing
While we continuously invest in improving diagnostic accuracy and usability, we recognize that NHS affordability is paramount. Future algorithm versions may cost more than £0.30 per diagnosis to process as we enhance capabilities, but our general goal remains keeping costs below the £1 threshold.
Why This Matters
- NHS Budget Sustainability: Clear, predictable costs that fit within constrained healthcare budgets
- Scalability: Low per-diagnosis cost enables widespread deployment across 8,000+ GP practices
- ROI Clarity: Cost per diagnosis well below typical GP consultation costs (£40+)
- No Usage Barriers: Affordable pricing encourages frequent use without financial penalty
- Future-Proof: Commitment tied to 2025 real terms, protecting against inflation
Market Opportunity
Total Addressable Market
Initial Target Market
Year 1-2: 50-100 early adopter GP practices (0.6-1.25% market penetration)
Year 3-5: 500-1,000 practices (6-12.5% penetration) with NHS trust partnerships
Revenue Model: Per-clinician subscription or per-consultation licensing
Future Expansion Opportunities
- Secondary care and hospital settings
- Private healthcare sector
- International markets (EU, Commonwealth)
- Additional clinical specialties
- Telemedicine and remote consultation platforms
Regulatory Pathway & Timeline
We are pursuing MHRA authorization as Class IIb Software as a Medical Device (SaMD). This is the proven pathway used successfully by similar clinical decision support tools.
Q4 2025 - Q1 2026
Clinical Advisory Board Formation
Recruit 3-5 practicing GP advisors. Define clinical scope and validation plan.
Q2-Q3 2026
Clinical Validation & ISO Certification
Multi-site clinical studies. ISO 13485, ISO 14971, IEC 62304 certification.
Q4 2026 - Q1 2027
MHRA Submission & Authorization
Regulatory submission. MHRA review and authorization process.
Q2-Q3 2027
Pilot Deployment
Early NHS partners. Real-world validation. Refinement based on feedback.
Q4 2027
General Availability
Full market launch. Scale to 50-100 practices in Year 1.
Seed Funding Allocation
£1,000,000 seed round strategically allocated across regulatory compliance, product development, and market entry:
- Regulatory pathway: ISO certification, quality management systems, MHRA submission
- Clinical validation studies across multiple NHS sites
- Product development: NHS EHR integration, platform scaling, security infrastructure
- Team expansion: Medical director, regulatory affairs manager, engineering team
- Go-to-market: NHS partnerships, pilot deployment, early customer acquisition
Use of Funds
Seed funding will be deployed strategically across regulatory approval, team expansion, and market preparation.
MHRA pathway, ISO certification, clinical validation studies, quality management systems
Engineering team expansion, NHS EHR integration, platform refinement, security infrastructure
Clinical advisor compensation, medical director hire, clinical validation team
NHS partnership development, early customer acquisition, pilot deployment support
Company formation, legal compliance, insurance, operational infrastructure
Team & Advisors
Founder
Maximus Smith - BSc Mathematics, Software Engineer
Founded HeAIth after successfully using AI to diagnose own medical condition, saving £200+ and months of waiting. Built working MVP in one week. Deep understanding of both technical AI implementation and patient/clinician needs.
Clinical Advisory Board (Forming)
Recruiting 3-5 practicing GPs and frontline NHS clinicians to guide all product and clinical decisions. Advisory board members receive equity compensation and play crucial role in ensuring clinical validity and NHS workflow integration.
Planned Hires (Post-Funding)
- Medical Director: Qualified clinician to lead clinical strategy and validation
- Regulatory Affairs Manager: MHRA submission and compliance expertise
- Senior Software Engineers (2): NHS integration and platform scaling
- Clinical Validation Specialist: Evidence generation and trial management
Investment Terms
Round Type
Seed Round (SAFE or Equity)
Target Raise
£1,000,000
Stage
Pre-seed / Seed
Timeline
Q1-Q2 2026
Ideal Investor Profile
- Healthcare-focused VCs or angel investors
- Investors with NHS or UK healthcare experience
- Impact investors focused on improving healthcare access
- MedTech or HealthTech sector specialists
- Strategic investors with NHS connections or regulatory expertise
Note: Detailed terms, valuation, and investment documentation available to qualified investors upon request. All investments subject to UK financial regulations and investor accreditation requirements.
Interested in Learning More?
We're actively engaging with investors who share our vision of improving NHS primary care through responsible AI implementation.
Contact Maximus Smith, Founder for:
- Detailed investment deck and financial projections
- Product demonstration (non-clinical)
- Due diligence materials
- Regulatory pathway documentation
- Market analysis and competitive landscape
Email: maximus.smith@heaith.co.uk
Subject: "Investment Inquiry"